Tag - ASP

Markets

Mackie ups Acerus Pharma PT to 50 cents from 40 cents

Mackie Research raised its price target for Acerus Pharmaceuticals (TSX:ASP, OTCQB:ASPCF) to 50 cents from 40 cents, reflecting an amended agreement with Aytu Biosciences (NASDAQ:AYTU) that would move their partnership...

July 31, 2019

Markets

Mackie starts Acerus Pharma at speculative buy; PT 50 cents

Mackie Research Capital initiated coverage of Acerus Pharmaceuticals (TSX:ASP) with a “speculative buy” rating and a 12-month target price of 50 cents. The stock closed at 26 cents on March 13. Acerus specializes in men...

March 14, 2018

Tag - ASP

Mackie ups Acerus Pharma PT to 50 cents from 40 cents

Mackie starts Acerus Pharma at speculative buy; PT 50 cents

General

More